CAMBRIDGE, MA / ACCESSWIRE / March 14, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that two abstracts on mRNA ...
mRNA-4157 (V940) is a novel investigational messenger ribonucleic acid (mRNA)-based individualized neoantigen therapy 1 consisting of a single synthetic mRNA coding for up to 34 neoantigens that is ...
After your surgery to remove the renal cell cancer, your doctor might treat you with pembrolizumab. The aim of this treatment is to reduce the risk of the cancer coming back. Research has shown that ...
Moderna, Inc. and Merck, known as MSD outside of the United States and Canada, announced the first presentation of results from a planned analysis from the phase 2b ...
Merck & Co. MRK and Moderna Inc. MRNA said Wednesday they have launched a Phase 3 trial of Moderna’s V940 in combination with Merck’s Keytruda as a treatment for patients with high-risk, or Stage ...
Phase 1 dose escalation (DEs) & expansion (DEx) study to evaluate the safety & efficacy of IDE397 plus sacituzumab-govitecan in patients with advanced urothelial carcinoma (UC) with MTAP deletion ...
After three years of study, the V940 and Keytruda combination demonstrated sustained benefits in recurrence-free survival and distant metastasis-free survival in patients with high-risk melanoma ...
Please note - this trial is no longer recruiting patients. We hope to add results when they are available. V940 is an immunotherapy. It is also called mRNA-4157. To make it, doctors analyse tissue and ...
Personalized cancer vaccines are designed to prime the immune system so that a patient can generate a tailored antitumor response specific to their tumor mutation signature. mRNA-4157/V940 is a novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results